Volume 11, Number 11—November 2005
Research
Cervical Human Papillomavirus Screening among Older Women
Table 3
Age (y, baseline) | HPV status – (1988) |
HPV status + (1988) |
% HPV acquisition in 3 y (95% CI) | % HPV clearance in 3 y (95% CI)* | ||
---|---|---|---|---|---|---|
– (1991) | + (1991) | – (1991) | + (1991) | |||
HPV16 | ||||||
21 | 79 | 3 | 3 | 1 | 3.7 (1.3–10.2) | – |
31 | 94 | 3 | 1 | 0 | 3.1 (1.1–8.7) | – |
41 | 94 | 3 | 3 | 0 | 3.1 (1.1–8.7) | – |
51 | 360 | 11 | 1 | 0 | 3.0 (1.7–5.2) | – |
Total | 627 | 20 | 8 | 1 | 3.1 (2.0–4.7) | 88.9 (56.5–98.0) |
HPV18 | ||||||
21 | 77 | 2 | 6 | 1 | 2.5 (0.7–8.8) | – |
31 | 89 | 5 | 3 | 1 | 5.3 (2.3–11.9) | – |
41 | 95 | 3 | 2 | 0 | 3.1 (1.0–8.6) | – |
51 | 352 | 14 | 5 | 0 | 3.8 (2.3–6.3) | – |
Total | 613 | 24 | 16 | 2 | 3.8 (2.5–5.5) | 88.9 (67.1–96.9) |
*Clearance rates of HPV 16/18 were not calculated for individual ages because of insufficient numbers; CI, confidence interval.
Page created: February 17, 2012
Page updated: February 17, 2012
Page reviewed: February 17, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.